Osaka-based pharmaceutical company Shionogi says it has started a clinical trial for Japanese adolescents aged 12 to 19 of a coronavirus vaccine it is developing for all age groups.
The product is a recombinant protein-based vaccine.
For adult usage, the company is set to apply for approval with Japanese authorities as early as next month.
The company said on Monday the clinical trial involves 350 adolescents. They will receive two doses to see whether their neutralizing antibody levels will equal those found in adults who have received the shots, or rise even higher.
The trial began last Saturday. The drugmaker says the participants will receive a third dose to see whether their antibody levels rise again.
Shionogi also plans a clinical trial for children 5 to 11. The company says it "will seek to provide new options for COVID-19 vaccination for people of all ages."
The product is a recombinant protein-based vaccine.
For adult usage, the company is set to apply for approval with Japanese authorities as early as next month.
The company said on Monday the clinical trial involves 350 adolescents. They will receive two doses to see whether their neutralizing antibody levels will equal those found in adults who have received the shots, or rise even higher.
The trial began last Saturday. The drugmaker says the participants will receive a third dose to see whether their antibody levels rise again.
Shionogi also plans a clinical trial for children 5 to 11. The company says it "will seek to provide new options for COVID-19 vaccination for people of all ages."
Similar Readings (5 items)
Novavax approved in Japan, expected to be available in late May
Japan starts new COVID vaccination program to counter expected winter case rise
Japan approves coronavirus vaccine aimed at Omicron
Japan to start giving Omicron-targeting vaccines
Scientists take aim at Omicron
Summary
Osaka-based Shionogi initiates clinical trial on a coronavirus vaccine for adolescents aged 12-19. The recombinant protein-based product is also in development for all age groups. Adult application for approval with Japanese authorities is planned for next month. The trial, involving 350
Statistics
145
Words1
Read CountDetails
ID: 62825d9a-64b8-4e86-8b4c-3018c0a80b98
Category ID: nhk
URL: https://www3.nhk.or.jp/nhkworld/en/news/20220516_24/
Date: May 16, 2022
Created: 2022/05/16 23:20
Updated: 2025/12/09 16:19
Last Read: 2022/05/16 23:20